Eosinophils—from cradle to grave
(2023) In Allergy: European Journal of Allergy and Clinical Immunology 78(12). p.3077-3102- Abstract
Over the past years, eosinophils have become a focus of scientific interest, especially in the context of their recently uncovered functions (e.g. antiviral, anti-inflammatory, regulatory). These versatile cells display both beneficial and detrimental activities under various physiological and pathological conditions. Eosinophils are involved in the pathogenesis of many diseases which can be classified into primary (clonal) and secondary (reactive) disorders and idiopathic (hyper)eosinophilic syndromes. Depending on the biological specimen, the eosinophil count in different body compartments may serve as a biomarker reflecting the underlying pathophysiology and/or activity of distinct diseases and as a therapy-driving (predictive) and... (More)
Over the past years, eosinophils have become a focus of scientific interest, especially in the context of their recently uncovered functions (e.g. antiviral, anti-inflammatory, regulatory). These versatile cells display both beneficial and detrimental activities under various physiological and pathological conditions. Eosinophils are involved in the pathogenesis of many diseases which can be classified into primary (clonal) and secondary (reactive) disorders and idiopathic (hyper)eosinophilic syndromes. Depending on the biological specimen, the eosinophil count in different body compartments may serve as a biomarker reflecting the underlying pathophysiology and/or activity of distinct diseases and as a therapy-driving (predictive) and monitoring tool. Personalized selection of an appropriate therapeutic strategy directly or indirectly targeting the increased number and/or activity of eosinophils should be based on the understanding of eosinophil homeostasis including their interactions with other immune and non-immune cells within different body compartments. Hence, restoring as well as maintaining homeostasis within an individual's eosinophil pool is a goal of both specific and non-specific eosinophil-targeting therapies. Despite the overall favourable safety profile of the currently available anti-eosinophil biologics, the effect of eosinophil depletion should be monitored from the perspective of possible unwanted consequences.
(Less)
- author
- organization
- publishing date
- 2023-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- allergic diseases, biologics, biomarker, COVID-19, eosinophils, non-allergic diseases
- in
- Allergy: European Journal of Allergy and Clinical Immunology
- volume
- 78
- issue
- 12
- pages
- 26 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:37702095
- scopus:85170692420
- ISSN
- 0105-4538
- DOI
- 10.1111/all.15884
- language
- English
- LU publication?
- yes
- id
- 4393ebc1-24c7-4e83-b113-0271bae316b8
- date added to LUP
- 2023-12-22 13:56:12
- date last changed
- 2024-04-20 23:11:35
@article{4393ebc1-24c7-4e83-b113-0271bae316b8,
abstract = {{<p>Over the past years, eosinophils have become a focus of scientific interest, especially in the context of their recently uncovered functions (e.g. antiviral, anti-inflammatory, regulatory). These versatile cells display both beneficial and detrimental activities under various physiological and pathological conditions. Eosinophils are involved in the pathogenesis of many diseases which can be classified into primary (clonal) and secondary (reactive) disorders and idiopathic (hyper)eosinophilic syndromes. Depending on the biological specimen, the eosinophil count in different body compartments may serve as a biomarker reflecting the underlying pathophysiology and/or activity of distinct diseases and as a therapy-driving (predictive) and monitoring tool. Personalized selection of an appropriate therapeutic strategy directly or indirectly targeting the increased number and/or activity of eosinophils should be based on the understanding of eosinophil homeostasis including their interactions with other immune and non-immune cells within different body compartments. Hence, restoring as well as maintaining homeostasis within an individual's eosinophil pool is a goal of both specific and non-specific eosinophil-targeting therapies. Despite the overall favourable safety profile of the currently available anti-eosinophil biologics, the effect of eosinophil depletion should be monitored from the perspective of possible unwanted consequences.</p>}},
author = {{Jesenak, Milos and Diamant, Zuzana and Simon, Dagmar and Tufvesson, Ellen and Seys, Sven F. and Mukherjee, Manali and Lacy, Paige and Vijverberg, Susanne and Slisz, Tomas and Sediva, Anna and Simon, Hans Uwe and Striz, Ilja and Plevkova, Jana and Schwarze, Jurgen and Kosturiak, Radovan and Alexis, Neil E. and Untersmayr, Eva and Vasakova, Martina Koziar and Knol, Edward and Koenderman, Leo}},
issn = {{0105-4538}},
keywords = {{allergic diseases; biologics; biomarker; COVID-19; eosinophils; non-allergic diseases}},
language = {{eng}},
number = {{12}},
pages = {{3077--3102}},
publisher = {{Wiley-Blackwell}},
series = {{Allergy: European Journal of Allergy and Clinical Immunology}},
title = {{Eosinophils—from cradle to grave}},
url = {{http://dx.doi.org/10.1111/all.15884}},
doi = {{10.1111/all.15884}},
volume = {{78}},
year = {{2023}},
}